Home
Conditions
Recurrent Primary Peritoneal Carcinoma

Clinical trial condition

Recurrent Primary Peritoneal Carcinoma

Explore clinical trials studying Recurrent Primary Peritoneal Carcinoma. Study availability and eligibility vary by location and protocol.

80 public trials 10 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Primary Peritoneal Carcinoma trial results

Completed

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03206047

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
Locations: Banner University Medical Center - Tucson Tucson, Arizona, United States

University of Arizona Cancer Center-North Campus Tucson, Arizona, United States

City of Hope Comprehensive Cancer Center Duarte, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View all 17 locations

View Trial Details

Completed

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471

Conditions: Adnexal Diseases, BRCA1 Gene Mutation, BRCA2 Gene Mutation, +24 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Completed

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02312245

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: Mayo Clinic in Arizona Phoenix, Arizona, United States

Mayo Clinic in Florida Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457

Conditions: Adnexal Diseases, BRCA1 Gene Mutation, BRCA2 Gene Mutation, +20 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

The Feinstein Institute for Medical Research/Lennox Hill Hospital New York, United States

View Trial Details

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01606241

Conditions: Adnexal Diseases, Breast Diseases, Breast Neoplasms, +45 more
Locations: Mayo Clinic Rochester, Minnesota, United States

View Trial Details

Completed

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients

NCT03539406

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: Radboudumc Nijmegen, Netherlands

View Trial Details

Completed

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

NCT02996825

Conditions: Adnexal Diseases, Breast Diseases, Breast Neoplasms, +25 more
Locations: City of Hope Medical Center Duarte, California, United States

City of Hope Upland Upland, California, United States

View Trial Details

Completed

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01001910

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: Columbia University Medical Center New York, United States

Memorial Sloan-Kettering Cancer Center New York, United States

Albert Einstein College of Medicine The Bronx, New York, United States

View Trial Details

Completed

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02901899

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations: Northwestern University Chicago, Illinois, United States

The University of Chicago Medicine Chicago, Illinois, United States

Northwestern Lake Forest Hospital Lake Forest, Illinois, United States

View Trial Details

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04753216

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations: Northwestern University Chicago, Illinois, United States

View Trial Details

Recurrent Primary Peritoneal Carcinoma

Recurrent Primary Peritoneal Carcinoma trial results

Related conditions